Skip to main content

CORRECTION article

Front. Endocrinol., 03 May 2019
Sec. Molecular and Structural Endocrinology
Volume 10 - 2019 | https://doi.org/10.3389/fendo.2019.00275
This article is part of the Research Topic GLP-1 analogues and DPP-4 inhibitors in type 2 diabetes therapy: from structural biology to clinics View all 8 articles

Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

This article is a correction to:

  1. Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

    1. Read original article
\nCarolyn F. Deacon*Carolyn F. Deacon*
  • Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

A Corrigendum on
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

by Deacon, C. F. (2019). Front. Endocrinol. 10:80. doi: 10.3389/fendo.2019.00080

In the original article, there was a mistake in Table 2 “Key published studies demonstrating the safety and tolerability of DPP-4 inhibitors” as published. Unfortunately, two of the citations were transposed in the table. The correct citation for the SAVOR-TIMI trial is Scirica et al. (2013): Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317–1326 (ref 127), while the correct citation for the TECOS trial is Green et al. (2015): Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373: 232–242, 2015 (ref 126). The corrected Table 2 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

TABLE 2
www.frontiersin.org

Table 2. Key published studies demonstrating the safety and tolerability of DPP-4 inhibitors.

Keywords: dipeptidyl peptidase-4, glucagon-like peptide-1, incretin, peptide degradation, therapy, type 2 diabetes

Citation: Deacon CF (2019) Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes. Front. Endocrinol. 10:275. doi: 10.3389/fendo.2019.00275

Received: 12 April 2019; Accepted: 15 April 2019;
Published: 03 May 2019.

Approved by:

Frontiers in Endocrinology Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2019 Deacon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Carolyn F. Deacon, deacon@sund.ku.dk

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.